文章预览
SCI 2 November 2024 The Risk and Reversibility of Osimertinib-related Cardiotoxicity in a Real-World Population (Journal of Thoracic Oncology, IF: 21.0) Minjung Bak, MD, Hyukjin Park, MD, Se-Hoon Lee, MD, Nuri Lee, MD, Myung-Ju Ahn, MD, Jin Seok Ahn, MD, Hyun Ae Jung, MD, Sehhoon Park, MD, Jinhyun Cho, MD, Jihoon Kim, MD, Sung-Ji Park, MD, Sung-A Chang, MD, Sang-Chol Lee, MD, Seung Woo Park, MD, Eun Kyoung Kim, MD CORRESPONDENCE TO: ekbobi.kim@samsung.com INTRODUCTION 简介 While osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, as the first-line therapy for metastatic non-small cell lung cancer (NSCLC) has shown significant survival benefits, concerns have arisen regarding its potential cardiotoxicity, particularly in real-world clinical settings. We aimed to investigate the incidence, risk factors, and reversibility of osimertinib-related cardiotoxicity. 尽管第三代表皮生长因子受体酪氨酸激酶抑制剂奥希替尼作为转
………………………………
